535 related articles for article (PubMed ID: 26883102)
21.
Smeets MF; Tan SY; Xu JJ; Anande G; Unnikrishnan A; Chalk AM; Taylor SR; Pimanda JE; Wall M; Purton LE; Walkley CR
Blood; 2018 Aug; 132(6):608-621. PubMed ID: 29903888
[TBL] [Abstract][Full Text] [Related]
22. Somatic SETBP1 mutations in myeloid neoplasms.
Makishima H
Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
[TBL] [Abstract][Full Text] [Related]
23. The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers.
Meggendorfer M; Haferlach C; Zenger M; Macijewski K; Kern W; Haferlach T
Leukemia; 2016 Jul; 30(7):1624-7. PubMed ID: 26859077
[No Abstract] [Full Text] [Related]
24. Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.
Cui Y; Tong H; Du X; Li B; Gale RP; Qin T; Liu J; Xu Z; Zhang Y; Huang G; Jin J; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Exp Hematol Oncol; 2015; 4():14. PubMed ID: 26019984
[TBL] [Abstract][Full Text] [Related]
25. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
Gurney M; Chekkaf I; Baranwal A; Basmaci R; Katamesh B; Greipp P; Foran JM; Badar T; Mangaonkar AA; Begna KH; Gangat N; Patnaik MM; Litzow MR; Shah MV; Viswanatha DS; He R; Alkhateeb HB; Al-Kali A
Br J Haematol; 2023 Jul; 202(2):279-283. PubMed ID: 37144345
[TBL] [Abstract][Full Text] [Related]
26. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
27. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract][Full Text] [Related]
28. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
29. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
30. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
Tashakori M; Khoury JD; Routbort MJ; Patel KP; Wang SA; Ok CY; El-Hussein S; Kanagal-Shamanna R; Luthra R; Hu S; Lin P; Pemmaraju N; Bose P; Verstovsek S; Bueso-Ramos CE; Medeiros LJ; Loghavi S
Mod Pathol; 2022 Nov; 35(11):1677-1683. PubMed ID: 35690645
[TBL] [Abstract][Full Text] [Related]
32. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
Han W; Zhou F; Wang Z; Hua H; Qin W; Jia Z; Cai X; Chen M; Liu J; Chao H; Lu X
Int J Hematol; 2022 Jan; 115(1):21-32. PubMed ID: 34449040
[TBL] [Abstract][Full Text] [Related]
33. Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course.
McClure RF; Dewald GW; Hoyer JD; Hanson CA
Br J Haematol; 1999 Aug; 106(2):445-54. PubMed ID: 10460605
[TBL] [Abstract][Full Text] [Related]
34. Concomitant isochromosome 17q and mutated
Xu Q; Liu C; Zhang H; Liu H; Xue M; Zhang S; Liu B
Int J Clin Exp Pathol; 2017; 10(9):9786-9792. PubMed ID: 31966863
[TBL] [Abstract][Full Text] [Related]
35. [Role of ASXL1 mutation in myeloid malignancies].
Sheng MY; Zhou Y; Xu MJ; Yang FC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive genomic profiling reveals molecular subsets of
Johnson SM; Haberberger J; Galeotti J; Ramkissoon L; Coombs CC; Richardson DR; Foster MC; Duncan D; Montgomery ND; Ferguson NL; Zeidner JF
Leuk Lymphoma; 2024 Feb; 65(2):209-218. PubMed ID: 37921062
[TBL] [Abstract][Full Text] [Related]
37. ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation.
Saika M; Inoue D; Nagase R; Sato N; Tsuchiya A; Yabushita T; Kitamura T; Goyama S
Sci Rep; 2018 Oct; 8(1):15873. PubMed ID: 30367089
[TBL] [Abstract][Full Text] [Related]
38. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations.
Adema V; Larráyoz MJ; Calasanz MJ; Palomo L; Patiño-García A; Agirre X; Hernández-Rivas JM; Lumbreras E; Buño I; Martinez-Laperche C; Mallo M; García O; Álvarez S; Blazquez B; Cervera J; Luño E; Valiente A; Vallespí MT; Arenillas L; Collado R; Pérez-Oteyza J; Solé F
Br J Haematol; 2015 Oct; 171(1):137-41. PubMed ID: 25716545
[No Abstract] [Full Text] [Related]
39. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
[TBL] [Abstract][Full Text] [Related]
40. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.
Shuai W; Zuo Z; Li N; Garces S; Jelloul FZ; Ok CY; Li S; Xu J; You MJ; Wang W; Rehder C; Jabbour EJ; Patel KP; Medeiros LJ; Yin CC
Cancer; 2023 Mar; 129(6):878-889. PubMed ID: 36583229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
